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Abstract – This paper reports the results of tissue infectivity assays of bovine spongiform encephalopathy
(BSE) agent in orally exposed cattle at stages during the incubation period. Estimations of the titre of
infectivity in central nervous system (CNS), certain peripheral nerve ganglia and distal ileum tissue were
made according to time post exposure from the relationship between incubation period and dose for RIII
mice and C57bl mice using data from titrations of brain material from cases of BSE. The rate of increase
of infectivity in the bovine CNS was then estimated, taking into account these tissue infectivity titres, the
variability of the brain titre of clinical ﬁeld cases of BSE, and the probability density of the expected number
of months before clinical onset of each infected bovine. The doubling time for CNS was shown to equal 1.2
months. The titre in the thoracic dorsal root ganglia (DRG) was, on average, approximately 1 log units less
than CNS, and cervical DRG approximately 0.5 log less than thoracic DRG. The pattern of increase of
infectivity in the distal ileum is that of an initial increase up to 14–18 months post exposure, followed by a
decrease, which is likely to be highly variable between animals. These results will be informative for future
risk assessments of BSE, especially in relation to reviewing current control measures.
bovine spongiform encephalopathy / pathogenesis / modeling / infectivity titres / maximum likelihood
estimation
1. INTRODUCTION
Results of oral exposure studies of
the pathogenesis of bovine spongiform
encephalopathy (BSE) in cattle, conducted
in the United Kingdom, have been reported
previously [1, 13, 25, 29–34]. The initial
study [32, 34] examined the distribution of
infected tissues in cattle exposed as calves to
100g of BSE infected brainstem and killed at
intervals throughout the course of the disease.
Tissues were collected at each kill time point
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post exposure (p.e.) for bioassay, initially, in
inbred mice. Previous reports of the study
have recorded infectivity detected by mouse
bioassay in the distal ileum (6–18 months and
36–40 months p.e.) and in the central nervous
system (CNS) (32–40 months p.e.); the earli-
est onset of deﬁnite clinical signs in the cattle
occurring at 35 months p.e. [32]. Infectivity
was also detected in certain sensory ganglia of
the peripheral nervous system (32–40 months
p.e.) and traces of infectivity were also shown
in sternal bone marrow, but only from cattle
killed 38 months p.e. [33].
Data from this oral exposure study were
used to tentatively classify certain tissues as
being of high, medium or low infectivity atVet. Res. (2009) 40:08 M.E. Arnold et al.
certain time periods post exposure1. However,
models of the BSE epidemic [8,14,15,20] and
assessments of the human risk of exposure to
the BSE agent [4, 5, 12, 18] require quantita-
tive estimates of the infectivity by stage of
incubation period and the data required to
produce such estimates have not previously
been available. Although the BSE epidemic
has declined to a very low prevalence [11]
such quantitative estimates remain of interest
as they are important in risk assessments of
the impact of potential human exposure on
relaxing BSE control measures.
The objective of this paper is to report
the completed results of the wild-type mouse
assays of infectivity of CNS, certain peripheral
nerve ganglia and distal ileum tissues taken
throughout the course of the initial UK
oral exposure study of experimental BSE
in cattle and to estimate the infectivity in
these tissues according to incubation period.
Of particular interest is the rate of increase
of infectivity, or doubling time, in CNS
which has a large impact on estimates of
potential human exposure in terms of bovine
oral ID50s [5, 16] and in the dorsal root
ganglia (DRG), which have been estimated to
have made the largest contribution to human
exposure to BSE in contaminated products
since the implementation of speciﬁed bovine
offal legislation in the early 1990s [5]. Also
of interest is the pattern of infectivity in distal
ileum over the course of the incubation period,
since it could have important implications for
the pathogenesis of BSE in cattle.
1 European Commission, Scientiﬁc Steering Com-
mittee Update of the Opinion on TSE Infectivity
distribution in ruminant tissues (Initially adopted
by the Scientiﬁc Steering Committee at its meet-
ing of 10–11 January 2002 and amended at its
meeting of 7–8 November 2002) following the
submission of (1) a risk assessment by the German
Federal Ministry of Consumer Protection, food and
Agriculture and (2) new scientiﬁc evidence regard-
ing BSE infectivity distribution in tonsils, 2002,
http://europa.eu.int/comm/food/fs/sc/ssc/outcome_
en.html#opinions.
2. MATERIALS AND METHODS
2.1. Experimental design of the cattle oral
exposure pathogenesis study
The study design has been described previ-
ously [31]. Brieﬂy, forty Friesian/Holstein calves,
born in 1991, were assembled from farms with no
history of BSE. At 4 months of age, 30 were each
dosed orally with 100g of homogenized pooled
brain stems obtained from 75 cases of BSE from
variouslocationsinEnglandandWales,slaughtered
in 1991 and conﬁrmed by histopathological exam-
ination. An end point titration of infectivity in the
pooled brainstem homogenate in RIII mice gave
a value of 103.5 intracerebral (i.c.)/intraperitoneal
(i.p.), mouse ID50 unit/g of tissue [22]. Ten calves
received no treatment and served as controls. Clin-
ical monitoring of cattle was maintained through-
out the period of study to detect the onset of clini-
cal signs consistent with BSE. Exposed and control
cattle were killed sequentially starting at six months
of age (Fig. 1).
A large range of tissues were sampled asepti-
callyateachsequentialkilltimepointforinfectivity
assays in inbred mice [31].
2.2. Mouse bioassay of cattle tissue infectivity
Inocula were prepared as previously
described [32] from a total of 52 tissues, rep-
resenting principally the lymphoreticular system,
the peripheral nervous system, the CNS, alimentary
tract, striated muscles and major viscera (see
supplementary material available online only,
Tab. IS). All inocula were prepared as ten per
cent suspensions in saline, with the inclusion
of antibiotics for certain tissues. Single tissue
inoculum pools were made from the exposed cattle
at each time point. Control inocula were similarly
prepared but from single tissues of each control
animal.
Test and control tissue inocula were each
assayed in 20 RIII, and/or C57bl inbred mice
according to standard procedures. Each mouse was
injected with 0.02mL by the i.c. route and 0.1mL
by the i.p. route. Detailed clinical monitoring of
the mice was carried out from 250 days post-
inoculation (p.i.) and the clinical end point when
mice show clear signs of neurological disease was
determined according to established criteria for
calculating incubation period [9]. The brain of
each mouse was removed, ﬁxed in 10% phosphate
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Figure 1. Schedule of sequential kill time points of exposed and control cattle.
∗ Kills continuing at 4 month intervals to 22 months p.i.; ex: exposed; co: control.
buffered formalin (BF), and processed routinely
for histopathological examination for evidence of
spongiform encephalopathy. Any mice surviving
to the end point for incubation and expression of
the disease were killed and examined similarly, as
were any mice that died or were killed due to
intercurrent disease. Previously determined assay
end points of 650 days, (occasionally, depending on
tissue, extended to 700 days) for RIII mice and 950
days for C57bl mice deﬁned the termination of the
assays.
2.3. Estimation of titres from incubation period
assay
Bioassay, using endpoint titration, is regarded to
be the most accurate method for the determination
of the concentration of infectivity of transmissible
spongiform encephalopathy agents in tissue. Esti-
mation of infectivity by end-point titration in mice
of tissues of cattle with BSE has been limited to the
study of CNS in terminal cases and there are as yet
no data on titration of any tissue at various stages
of incubation. Although regarded as less accurate,
dose-response relationships have been used as a
method for infectivity estimation [10,26] when end-
point titration data are not available. In this study,
we adopt a method that is similar in principle to
incubation period assay [10,26] but also takes into
account the proportion of mice which become clin-
ical, providing a more accurate estimate of titre
at lower doses than solely using the mean incuba-
tion period. To derive the dose/incubation relation-
ship to be used to convert the incubation periods
from the RIII mouse bioassay into titres of infectiv-
ity, data were analysed from titrations in RIII mice
of several different pools of brain material (whole
brain or brain stem) from clinical ﬁeld cases of BSE
(see supplementary material available online only,
Fig. 1S). The method is then as follows.
There are two potential outcomes for each
mouse; either it could become clinical at t
months post-inoculation, with probability Pc(t),
or it could die due to causes unrelated to BSE
(through intercurrent disease or be sacriﬁced at
the experimental end point), with probability PS(t).
Denoting the titre of inoculum to which the
individual mouse was exposed by , and denoting
the dose-dependent probability of infection and
incubation period (IP) by S(), f() respectively
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these outcomes are given by:
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i,Twere the number of mice which
became clinical and the number of mice which
die without showing clinical signs respectively for
tissue i taken from cattle at T months p.e., and
tj is the IP of the jth mouse. Estimates of the
titre for each positive tissue for each time point are
obtained by maximising the log-likelihood given in
equation (3).
2.4. Estimation of rate of increase of the titre of
infectivity in bovine CNS
An exponential increase with constant rate has
been observed experimentally in scrapie infected
hamsters [2, 7] for prion protein and titre of
infectivity in the CNS tissues as time p.i. increased.
It has also been assumed in modelling and risk
assessments that the titre of infectivity increases
according to an exponential with constant rate in
BSE in cattle [4, 5, 8, 19, 20]. The assumption is
also made in this study and corresponds to a linear
increase in the log titres of infectivity as time post
infection increases, or, in terms of clinical onset, a
linear decrease in the log titres of infectivity in CNS
as time before clinical onset increased, i.e.
d() = d(0) −  (4)
where d(), d(0) represent the titre of infectivity in
the CNS at  months before and at clinical onset
respectively, and  is the growth rate of the titre of
infectivity.
It was assumed that  is the same in each of the
different parts of the CNS.
While the estimates of titre by time point
from the 100g dosed cattle are useful for
investigations of the pathogenesis of BSE and
for gaining an understanding of the relative
infectiousness of different tissues, they have only
limitedapplicabilitytoﬁeldcasessincethemajority
of which had much longer incubation periods,
reﬂecting lower exposures [1]. Therefore, it is
useful for risk assessment purposes to have the
estimate of titre in terms of the number of months
before clinical onset, as this will correct for
differences in the incubation period distribution
between the 100g dosed animals and low exposures
in ﬁeld cases. It also enables the use of the
knowledge of the titre of infectivity at clinical onset
in ﬁeld cases (given below). Although the number
of months before onset for the sub-clinical cattle
in a sequential kill study cannot be determined, the
results from an oral attack rate study [35] provide
the incubation period distribution of cattle given
a 100g dose and hence the probability density
of the number of months before clinical onset (a
lognormal distribution with parameters  = 3.78,
 = 0.20 with left truncation at the age of culling).
Therefore the likelihood of the RIII mouse bioassay
data was calculated by integrating over all possible
valuesofthenumberofmonthsbeforeclinicalonset
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where S, f,  are as in equations (1) and (2),  is the
number of months before clinical onset of the cattle
fromwhichthetissuewastaken, ˆ f istheprobability
density function of the cattle incubation period
given the 100g oral dose, and ˆ F is the cumulative
distribution function of the cattle incubation period.
The (1– ˆ F) term in the denominator accounts for
the left truncation of the incubation period (since
the incubation period could not be shorter than the
culling age of the cattle as cattle were culled if they
reached clinical onset).
From titrations conducted in mice on brain from
clinical or clinical suspect cases of BSE (at VLA
or at the former Neuropathogenesis Unit, Institute
of Animal Health, Edinburgh), a wide range of
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titres have been obtained: 102.4–105.2 mouse i.c.
or i.c./i.p. ID50/g2,3 [17, 24, 28]. These data were
used to estimate the titre at clinical onset and
its variability. From this, the mean titre of brain
at clinical onset was given by 3.3, with standard
deviationof0.58.Thelog-likelihoodofthedatawas
then given as in equation (1) but with an additional
step of integrating over all possible values of the
clinical titre.
The rate of increase of infectivity, , was found
by maximising the log-likelihood of the mouse
bioassay data (1) for the caudal medulla and spinal
cord tissues, consisting of four data points at each
of the four time points selected. The frontal cortex
wasomittedasthe40monthtimepointwastheonly
one for this tissue where the titre could be estimated
with sufﬁcient precision.
The variability of the titre at a given number of
months p.e. was explored by taking 10000 random
draws from the incubation period distribution
for the 100g dose (using the bovine dose-
response relationship estimated previously [35],
10000 random draws from the clinical titre
distribution, and calculating the resulting titre using
the estimated rate of increase of infectivity in
CNS. The ﬁt of the exponential increase model
was checked by comparing the expected number of
infected mice of each strain at each time point with
the observed for each of the four CNS tissues.
2.5. The titre of infectivity in dorsal root ganglia
The data on mouse bioassay of DRG were
used to investigate how the infectivity in the DRG
varies through the incubation period relative to the
CNS. The relative timing of detectable infectivity
relative to clinical onset for the dorsal root ganglia
has been investigated in [1]. This showed that
there were differences in the timing of detectable
infectivity between the dorsal and cervical DRG,
suggesting that the titres of infectivity could differ
between them. Therefore, the titre of infectivity
was estimated separately for the dorsal and cervical
DRG, and since there were limited data, the titre
was estimated separately for each part of the DRG
for each time point, rather than a trend estimated.
The titres were estimated in terms of time p.e.
so that equations (1) and (2) were used for the
log-likelihood.
2 Wells G.A.H., Hawkins S.A.C., unpublished.
3 Bruce M., Taylor D.M., personal communication.
2.6. The titre of infectivity in distal ileum
Estimates of the rate of increase of infectivity
were attempted from the data on distal ileum at
different time points p.e. in the cattle study. It has
been reported previously that in the experimental
oral exposure of cattle, infectivity in the distal
ileum was detected at 6, 10, 14, 18, 36, 38 and
40 months but not at 32 months p.e.1 and from
6–14 months p.e. infectivity showed a rising titre
as indicated by decreasing mean incubation periods
in the assay mice [30, 31]. There are no data on
infectivity in distal ileum for the kill time points 22
and 26 months post exposure for RIII mice, and it
is therefore uncertain how the titre of infectivity in
the distal ileum might vary over the full range of
the incubation period. Since the infectivity in distal
ileum appears to peak far before clinical onset the
estimates were produced in terms of months post
exposure rather than months before clinical onset.
The estimates of titre in the distal ileum were
obtained using the method of Section 2.3, and the
same RIII mouse dose-response curve as was used
for the CNS tissues.
3. RESULTS
The results of the RIII and C57bl mouse
bioassays for which there was at least one
positive mouse are given in Table I.
The IP data for the C57bl mice were highly
variable and many of the individual IPs were
outside the range recorded in the available
titration data of brain homogenate in C57bl
mice, and so only the data on the number
of positive mice were used which correlated
closely with the number of RIII mice positive.
All other tissues were negative at all time
points, with the exception of bone marrow,
whichwaspositiveat38monthsp.e.only[33].
The upper 95% conﬁdence interval of the
maximum titre consistent with the data for
the negative tissues varied according to the
mean survival time of the mice inoculated
with the respective tissue; the power of the
study is lessened by intercurrent death. From
the RIII data the negative tissue assayed for
which there was the lowest mean survival
time in the mice was the trigeminal ganglia
at 32 months p.e., with a mean survival time
of 237 days and 4 mice surviving to end
point; the upper 95% conﬁdence interval for
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Table I. Survival data and mean incubation periods of RIII and C57bl mice inoculated i.c./i.p. with tissues
pooled from cattle at time intervals after the cattle were orally dosed with 100g of BSE affected brain stem
homogenate [32]. Data for tissues and time intervals where transmissions were negative are omitted.
Tissue Time post RIII C57bl
exposure No. of mice Mean No. of mice Mean
(months) +ve/No. of incubation +ve/No. of incubation
mice surviving period (days) mice surviving period (days)
when ﬁrst (SEM) when ﬁrst (SEM)
mouse mouse
conﬁrmed +ve conﬁrmed +ve
Distal ileum 6 10/12 523.7 (17.5) – –
10 14/17 511.4 (15.2) – –
14 15/18 455.0 (12.8) – –
18 18/18 470.7 (12.3) – –
36 0/10 N/A 1/2 942.0 (–)
38 4/14 581.5 (33.2) 4/12 791.3 (48.8)
40 14/17 538.2 (16.9) 8/19 644.4 (32.8)
Caudal medulla 32 6/17 584.9 (24.9) 7/16 743 (33.4)
36 7/14 554.9 (19.2) 12/19 707 (24.2)
38 14/18 486.9 (18.1) 14/19 608.3 (37.2)
40 11/12 485.0 (12.8) 14/20 637.5 (34.7)
Cervical spinal cord (C2-3) 32 2/16 596.0 (57.0) 6/20 840.8 (38.7)
36 5/13 565.4 (28.3) 7/14 733.9 (19)
38 10/17 555.1 (18.7) 9/19 675.4 (24.5)
40 16/20 477.6 (10.8) 11/16 687.1 (27.7)
Thoracic spinal cord (T10-11) 32 2/15 523.0 (74.0) 8/19 787.4 (44.1)
36 15/19 554.5 (13.8) 13/18 716.2 (21.7)
38 8/17 576.2 (15.6) 6/19 703.2 (52.4)
40 13/18 457.5 (11.7) 14/19 627.6 (25.4)
Lumbar spinal cord (L3-4) 32 3/15 570.0 (39.8) 9/19 730.6 (32.8)
36 9/15 523.7 (15.2) 11/19 670.8 (28.9)
38 13/16 526.2 (16.2) 15/20 659.7 (25.7)
40 16/18 485.5 (13.7) 11/17 666.3 (32.5)
Frontal cortex 36 1/12 552.0 (–) 0/4 N/A
38 1/10 642.0 (–) 2/18 690.5 (135.5)
40 10/14 568.0 (18.5) 7/14 837.3 (38.3)
Thoracic DRG (T5-8) 32 3/18 541.7 (42.8) 3/10 807.3 (38.4)
36 8/20 531.9 (25.1) 9/18 654.4 (22.5)
38 0/7 N/A 1/18 614.0 (–)
40 9/20 587.6 (20.7) 4/14 754.8 (32.5)
Cervical DRG (C3-6) 32 0/8 N/A 1/10 817.0 (–)
36 4/17 553.2 (33.3) 3/16 722.3 (8.5)
38 1/15 552.0 (–) 0/3 N/A
40 1/9 652.0 (–) 0/3 N/A
Trigeminal ganglion 36 0/14 N/A 2/18 570 (70)
38 3/13 520.7 (24.8) 3/16 722 (55)
40 4/14 548.5 (41.9) 1/2 894.0 (–)
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Figure 2. The predicted (solid line) versus the observed proportion of mice infected (+ RIII, * C57bl) at
each time point assuming exponential growth in CNS tissues.
the estimated titre in this tissue was 10−1.3
RIII mouse i.c./i.p. ID50/g. All other negative
tissues can be considered to have a titre of
infectivity less than 10−1.3 RIII mouse i.c./i.p.
ID50/g. For the C57bl data, it is impossible
to establish the upper 95% conﬁdence interval
of the titre with any accuracy since the IP
distribution is not known.
3.1. Estimation of rate of increase of the titre of
infectivity in CNS
The estimated rate of increase of infectivity
in the CNS was 0.25log10 mouse i.c./i.p. units
per month (95% conﬁdence interval of 0.22–
0.27), giving a doubling time of 1.2 months
(95% conﬁdence interval of 1.1–1.4 months).
Assuming a mean titre of infectivity of
3.3 log10 mouse i.c./i.p. ID50/g, and given
the mean incubation period for the 100g
dosed cattle is approximately 45 months,
using the dose-response relationship estimated
previously [35], this gives mean titres of
infectivity of 0.1, 1.1, 1.6, 2.1 log10 mouse
i.c./i.p. ID50/g for 32, 36, 38 and 40 months
p.e.respectively(andameanof1.23acrossthe
4 time points). From these titres, the predicted
versus the actual proportion of mice that
succumbed to BSE at each time point is given
in Figure 2. The infectivity in the CNS tissues
can also be expressed in terms of bovine
oral ID50/g utilising results from a cattle
oral attack rate study where the inoculum
was of a known titre in terms of mouse
i.c./i.p. ID50/g [35]; this gives mean titres
of infectivity of −2.7,−1.7,−1.2,−0.7 log10
bovine oral ID50/g for 32, 36, 38 and
40 months p.e. respectively. However, the
variability of titres for a given time p.e.
will be considerable since there is variability
in both the incubation period distribution
and the titre at clinical onset. For example,
at 40 months p.e. for 100g dosed cattle,
simulations showed that the titre of infectivity
in CNS could vary between negligible levels
and an upper 97.5 percentile of 0.8log10
bovine oral ID50/g. Lower dosed cattle will
have lower titres of infectivity in CNS for a
given number of months p.e. For example,
cattle with a mean incubation period of
∼60 months would have a mean titre of
infectivity ∼14 × 0.25 = 3.5 loglog10 bovine
oral ID50/g lower than the 100g dosed cattle
in this experiment for a given number of
months p.e.
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Table II. Estimates of the titre of infectivity for dorsal root ganglia and distal ileum in 100g orally dosed
cattle at various time points post exposure.
Tissue Time post exposure Titre 95% CI
(months)
Thoracic DRG (T5-8) 32 0.38 (0.01, 0.71)
36 0.79 (0.54, 1.04)
38 –0.30 (–1.42, 0.3)
40 0.49 (0.21, 0.76)
Cervical DRG (C3-6) 32 –0.17 (–1.29, 0.45)
36 0.34 (0.11, 0.64)
38 –0.18 (–1.1, 0.39)
40 –0.58 (–1.91, 0.21)
Distal ileum 6 1.01 (0.67, 1.36)
10 1.10 (0.80, 1.41)
14 1.59 (1.27, 1.94)
18 1.58 (1.27, 1.91)
36 0.08 (–1.12, 0.64)
38 0.88 (–0.06, 1.15)
40 1.29 (1.05, 1.54)
3.2. Infectivity in dorsal root ganglia
The titre in the DRG was highly variable
(Tab. II). A likelihood ratio test showed that
there was a signiﬁcant difference between
the titre of the cervical and thoracic DRG;
there was an 11.1 higher log-likelihood for 4
additional parameters for the model assuming
different titres of infectivity between between
the cervical and thoracic DRG, compared to a
model assuming the same titres (p<0.001).
The mean titre in the thoracic DRG at the
4 time points was 0.34log10 mouse i.c./i.p.
ID50/g (from results in Tab. II), approximately
0.5log10 mouse i.c./i.p. ID50/g higher than
the cervical DRG, which had a mean titre of
−0.15log10 mouse i.c./i.p. ID50/g. The titre
in the DRG was lower than CNS, with the
thoracic and cervical DRG having mean titres
approximately 1 and 1.5log10 mouse i.c./i.p.
ID50/g lower than CNS respectively.
3.3. The pattern of infectivity in distal ileum
The titre of infectivity peaked in the distal
ileum at 14 months post-inoculation, with a
similar titre at 18 months (Tab. II). The titres
at 36, 38 and 40 months post exposure are
lower, suggesting a decline in the titre of
infectivity, in contrast to experimental rodent
models of scrapie where infectivity has been
found to plateau in lymphoreticular tissues and
the central nervous system [23]. These results
for cattle correspond to the hypothesis that
infectivityinitiallyincreases inthedistalileum
but later decreases in conjunction with the age
associated involution of lymphoid tissue in the
ileum [29].
4. DISCUSSION
The range of doubling times for CNS
infectivity presented here are lower than those
assumed previously [4], which was between
2 and 4 months. Moreover the best ﬁtting
value in this study (1.2 month) was outside
the previous range of values. Changes in the
estimate of CNS infectivity doubling time
wouldaffectestimatesofpotentialhumanfood
chain exposure as lower values of the doubling
time result in lower infectivity levels of CNS
of the cattle that evade detection. Therefore, if
the results of this study were used in place of
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thoseofthepreviousestimateitwouldresultin
lower estimates of human exposure of infected
cattle tissues from relaxation of the Over
Thirty Months rule in Great Britain whereby
all cattle over thirty months slaughtered in
the UK were removed from the human food
chain), than those given previously [16].
An estimate of the doubling time of
infectivity in CNS has been previously
produced [8], where the doubling time was
inferred from the dose-incubation response
curve from an oral attack rate study for BSE in
cattle [35]. Using the reduction in incubation
period from a 10-fold increase in dose, it was
estimated that the doubling time of infectivity
for BSE in cattle was 6 weeks, which is close
to the estimates provided in the present study
from mouse bioassay data.
The doubling times and titres of infectivity
in the CNS in this study were calculated for
100g dosed cattle. Assuming that doubling
times of infectivity are independent of initial
dose, the results of this study allow estimation
of titres according to months p.e. of lower
dosed cattle by employing the incubation
period distribution [35], the clinical titre
distribution, and the doubling time. Such
an extrapolation is very important for risk
assessments of potential human exposure,
since ﬁeld cases would rarely, if ever, have
been exposed to doses as high as 100g.
H o w e v e r ,i tw o u l db ev e r yu s e f u lt oh a v e
veriﬁcation that the rates of increase of
infectivity in CNS are independent of the
initial dose. Data from a recent study of the
timing of detectable PrPSc in cattle dosed
orally with 1g or 100g of BSE affected brain
tissue [1] showed clear differences between
the two doses in the number of months before
clinical onset that detectable PrPSc occurred
in the CNS, suggesting the possibility of
differences in the rate of increase of infectivity
in CNS for the different dose groups. There are
tissues available from the CNS of 1g dosed
cattle from [1]. If funding were available, then
bioassay using transgenic mice of the available
CNS tissues for 1g dosed cattle would help to
resolve this.
It was assumed that the titres were the same
in each part of the spinal cord and the caudal
medulla. However, it is possible that there are
small differences in titre between these tissues
since probable speciﬁc routes of entry of agent
to the CNS [21] suggest preferential sites for
the earliest CNS replication. When the timing
of ﬁrst detectable PrPSc relative to clinical
onset was estimated for a range of CNS
tissues in two sequential kill pathogenesis
studies [1], small differences in the timing
of ﬁrst detection were found between CNS
tissues. In particular, the rostral medulla was
found to have detectable PrPSc ∼0.7 months
before the lumbar and thoracic spinal cord,
w h i c hi nt u r nw e r e∼0.2 months in advance of
initial PrPSc detection in cervical spinal cord.
Such differences in the timings of detection, if
they translate into lag times for the occurrence
of infectivity, would be too small to detect in
the present study.
While the results presented here are for
bioassay of BSE in wild type mice, the
bioassay results in cattle of selected tissues
from the same experimental study source [34]
equate well with those assays conducted in
mice, in that the more sensitive cattle assay
has largely only conﬁrmed the mouse assay
results for which cattle tissues are infectious4.
Indeed, assays of pooled spleens from British
BSE affected cattle and a range of tissues
from a terminally affected cow in Germany
by inoculation of Tgbov XV mice, which
overexpress the bovine PrP gene, also failed to
reveal infectivity in additional tissues [3].
The results in Table II suggest that the
titre of infectivity in the DRG is much lower
than that of CNS. This result is important in
terms of risk assessment of potential human
exposure, since at the time of the OTM rule
review, it was estimated that approximately
90% of the bovine oral infectious units
entering the food supply was from DRG in
meat [5]. For this estimate, a pessimistic
assumption of the titre of infectivity in DRG
was equal to that in CNS. The results of
this study provide some basis to amend that
assumption, and this would have a large effect
on the proportion of human exposure from
DRG. However, lower estimates of human
4 Wells G.A.H., Hawkins S.A.C., unpublished data.
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exposure to bovine oral ID50s in the food chain
implies a low cattle-human species barrier [6]
since there would have been less human
exposure to produce the observed number of
human vCJD cases.
The results for DRG for the present
study are also of interest in relation to
the pathogenesis of BSE. Based on PrPSc
detection it has been suggested that DRG are
only infected in concert with, or after the
CNS [1,25]. The results here provide support
for this, since the titres of infectivity were
lower in DRG than spinal cord, suggesting
a later timing of entry. However, although
inconsistent detection of PrPSc in DRG among
animals, even after clinical onset [1], suggests
that any retrograde spread from CNS to DRG
might be highly variable between animals, and
this variability is a likely explanation of the
lack of a strong pattern of growth of infectivity
in the DRG (Tab. II).
The maximum titre of infectivity in the
distal ileum, occurring at 14 months, was
similar to that of the CNS tissues at
approximately 6 months before clinical onset
(Tab. II). However, since the infectivity in
distal ileum is, in all probability, conﬁned
largely to the Peyer’s patches, the total load
of infectivity will be lower than that of CNS,
since the mass of infected tissue in the distal
ileum will be far smaller than that of the CNS.
Furthermore, it is possible that the incubation
period to dose relationship is different for
distal ileum and CNS tissues [27]. This could
affect the estimates of titre for the distal ileum.
A change in the dose-response curve would
affect the best ﬁtting estimates of the titre
at each time point, but would not affect the
observed pattern of an initial increase in distal
ileum infectivity in the months immediately
following exposure, followed by a decrease
later in the incubation period.
This study has shown that the rate of
increase of infectivity in CNS tissues is 0.25
log units of mouse i.c./i.p. ID50/g per month;
equivalent to a doubling time of 1.2 month. It
has also shown that the titre in the thoracic
DRG is, on average, approximately 1 log
mouse i.c./i.p. ID50/g less than CNS, and
cervical DRG on average approximately 0.5
log mouse i.c./i.p. ID50/g less than thoracic
DRG. The pattern of increase of infectivity in
the distal ileum is that of an initial increase
up to 14–18 months post exposure, followed
by a decrease, which is likely to be highly
variable between animals. These results will
be informative for future risk assessments
of BSE, especially in relation to reviewing
current control measures.
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